on FERMENTALG (EPA:FALG)
Fermentalg structures its transformation to support its ambitions
Fermentalg, a major player in bio-solutions based on aquatic microorganisms, continues its strategic transformation under the leadership of Pierre Josselin. With a large patent portfolio and partnerships with industrial leaders such as HuvePharma, Givaudan and Suez, the company stands out in sustainable development and global health.
The Libourne-based company is restructuring its sales organisation to target priority markets, particularly food supplements, infant nutrition and cosmetics, in order to achieve significant market shares. It is banking on a renewed customer approach and geographical expansion, particularly in the United States and China.
Fermentalg aims to increase its turnover sixfold by 2026, reaching more than €25 million. This development is based on the industrialization of new products and the optimization of production costs, with the objective of a balanced EBITDA in 2026.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all FERMENTALG news